| アブストラクト | BACKGROUND: Changing disease dynamics and access to COVID-19 vaccines in Japan warrant a timely description of the burden of severe disease. Here we report inpatient healthcare resource utilization of COVID-19 in Japan and contextualize results with influenza. METHODS: We selected persons hospitalized for COVID-19 (ICD-10 code U07.1) from April 1, 2020-January 31, 2024 or influenza (ICD-10 code J09.X-J11.x) from November 1, 2017-October 31, 2019 from Medical Data Vision, a large hospital-based database in Japan. Outcomes of interest were length of stay, intensive care unit (ICU) admission, receipt of invasive mechanical ventilation (IMV), and inpatient mortality, assessed overall, as well as stratified by age groups and calendar time. FINDINGS: Among 5684 hospitalized COVID-19 cases, persons were older (median age 80 vs 64) and had a longer length of stay (median 21 vs 5 days) than the 18,584 influenza cases. The proportions of COVID-19 patients admitted to ICU (3% vs 1%), received IMV (6% vs 3%) and died in hospital (12% vs 3%) were higher compared to those of influenza patients. Burden was higher in adult COVID-19 patients than pediatric COVID-19 patients; however, COVID-19 burden surpassed influenza burden for both adults and pediatric patients. Inpatient burden of COVID-19 between May 2023 and January 2024 remained greater than that of influenza, with five times longer length of stay, three times the frequency of ICU care, twice the IMV support and four times the in-hospital deaths. INTERPRETATION: These findings underscore the need for continued prevention and treatment of COVID-19 to prevent severe disease. |
|---|
| ジャーナル名 | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
|---|
| Pubmed追加日 | 2025/5/1 |
|---|
| 投稿者 | Andersen, Kathleen M; Brouillette, Matthew A; Togo, Kanae; Tanabe, Kosuke; Carter, Benjamin T; Kent, Matthew T; Ding, Yingjie; Curcio, Daniel; Welch, Verna; McGrath, Leah J; Ilyas, Bushra; Ito, Shuhei |
|---|
| 組織名 | Pfizer Inc., 66 Hudson Boulevard East, New York, NY, 10001, United States.;Electronic address: Kathleen.andersen@pfizer.com.;Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-ku, Tokyo, 151-8589, Japan.;Genesis Research Group, 111 River Street Suite 1120, Hoboken, NJ, 07030, United;States. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40306488/ |
|---|
